1377 related articles for article (PubMed ID: 17437432)
1. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
3. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
4. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
[TBL] [Abstract][Full Text] [Related]
5. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
Spiess PE; Tannir NM; Tu SM; Brown GA; Liu P; Kamat AM; Wood CG; Evans JG; Pisters LL
Cancer; 2007 Dec; 110(12):2700-8. PubMed ID: 17948916
[TBL] [Abstract][Full Text] [Related]
6. Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome.
Ong TA; Winkler MH; Savage PM; Seckl MJ; Christmas TJ
BJU Int; 2008 Jul; 102(2):198-202. PubMed ID: 18294302
[TBL] [Abstract][Full Text] [Related]
7. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
[TBL] [Abstract][Full Text] [Related]
8. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
[TBL] [Abstract][Full Text] [Related]
9. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
[TBL] [Abstract][Full Text] [Related]
10. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
11. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
12. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
13. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
14. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
15. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
[TBL] [Abstract][Full Text] [Related]
17. [Retroperitoneal lymphadenectomy in disseminated non-seminoma germinogenic testicular tumors after chemotherapy in patients with elevated serum tumor markers].
Matveev VB; Volkova MI; Cherniev VA; Figurin KM; Mitin AV
Urologiia; 2010; (3):41-7. PubMed ID: 20734877
[TBL] [Abstract][Full Text] [Related]
18. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer.
Spiess PE; Brown GA; Liu P; Tannir NM; Tu SM; Evans JG; Czerniak B; Kamat AM; Pisters LL
Cancer; 2006 Oct; 107(7):1483-90. PubMed ID: 16944541
[TBL] [Abstract][Full Text] [Related]
19. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
20. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
Eggener SE; Carver BS; Loeb S; Kondagunta GV; Bosl GJ; Sheinfeld J
Cancer; 2007 Feb; 109(3):528-35. PubMed ID: 17177200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
